MX359651B - Antagonistas de cxcr7. - Google Patents

Antagonistas de cxcr7.

Info

Publication number
MX359651B
MX359651B MX2015006412A MX2015006412A MX359651B MX 359651 B MX359651 B MX 359651B MX 2015006412 A MX2015006412 A MX 2015006412A MX 2015006412 A MX2015006412 A MX 2015006412A MX 359651 B MX359651 B MX 359651B
Authority
MX
Mexico
Prior art keywords
cxcr7
pharmaceutically acceptable
compounds
formula
cxcr7 antagonists
Prior art date
Application number
MX2015006412A
Other languages
English (en)
Other versions
MX2015006412A (es
Inventor
Fan Junfa
w lange Christopher
p mcmahon Jeffrey
Krasinski Antoni
M Lui Rebecca
P Powers Jay
Zeng Yibin
Zhang Penglie
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2015006412A publication Critical patent/MX2015006412A/es
Publication of MX359651B publication Critical patent/MX359651B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos que tienen la fórmula I, (ver Fórmula) O sales, hidratos o N-óxidos farmacéuticamente aceptables de los mismos y son útiles para la unión a CXCR7, para el tratamiento de enfermedades que son dependientes, al menos en parte, de la actividad de CXCR7. Por consiguiente, la presente invención proporciona en aspectos adicionales, composiciones que contienen uno o más de los compuestos indicados anteriormente en mezcla con un excipiente farmacéuticamente aceptable.
MX2015006412A 2012-11-29 2013-11-26 Antagonistas de cxcr7. MX359651B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731463P 2012-11-29 2012-11-29
PCT/US2013/072067 WO2014085490A1 (en) 2012-11-29 2013-11-26 Cxcr7 antagonists

Publications (2)

Publication Number Publication Date
MX2015006412A MX2015006412A (es) 2015-10-29
MX359651B true MX359651B (es) 2018-10-05

Family

ID=50825654

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006412A MX359651B (es) 2012-11-29 2013-11-26 Antagonistas de cxcr7.

Country Status (16)

Country Link
US (5) US9169261B2 (es)
EP (1) EP2925745B1 (es)
JP (1) JP6272897B2 (es)
KR (1) KR102196374B1 (es)
CN (1) CN105189484B (es)
AU (1) AU2013352304C1 (es)
BR (1) BR112015012366A8 (es)
CA (1) CA2892042C (es)
DK (1) DK2925745T3 (es)
ES (1) ES2681593T3 (es)
IL (1) IL238974B (es)
MX (1) MX359651B (es)
PT (1) PT2925745T (es)
RU (1) RU2649004C2 (es)
SG (1) SG11201504212WA (es)
WO (1) WO2014085490A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102196374B1 (ko) 2012-11-29 2020-12-31 케모센트릭스, 인크. Cxcr7 길항제
JP2017528461A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 置換ピロリジンカルボキサミド化合物
ES2929355T3 (es) * 2015-02-24 2022-11-28 Bayer Cropscience Ag Procedimiento para la preparación de triazoles
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
KR102497095B1 (ko) * 2016-07-28 2023-02-06 이도르시아 파마슈티컬스 리미티드 피페리딘 cxcr7 수용체 조절제
JP7240319B2 (ja) * 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
EP3713934B1 (en) 2017-11-23 2022-04-13 Universita' degli Studi di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
TWI822724B (zh) * 2018-01-26 2023-11-21 瑞士商愛杜西亞製藥有限公司 唑-3-羰基]-胺基}-哌啶-3-羧酸(1-嘧啶-2-基-環丙基)-醯胺之結晶型
CN108794484B (zh) * 2018-04-28 2020-04-24 北京施安泰医药技术开发有限公司 [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用
JP7590084B2 (ja) 2018-12-12 2024-11-26 ケモセントリックス，インコーポレイティド 癌治療のためのｃｘｃｒ７阻害剤
CN110013483B (zh) * 2019-05-10 2022-04-15 江苏师范大学 噻唑并[3,2-a]嘧啶-6-甲腈衍生物用于抗菌的用途
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
WO2021221444A1 (ko) 2020-04-27 2021-11-04 주식회사 오토텍바이오 Ubr 박스 도메인 리간드로의 화합물
CN113105469B (zh) * 2021-04-13 2022-04-22 中国科学院新疆理化技术研究所 一种三环呋喃并[2,3-d]嘧啶酮类化合物及用途
AU2022261722B2 (en) * 2021-04-19 2026-02-05 Chemocentryx, Inc. Azetidinyl-acetamides as cxcr7 inhibitors
CA3265709A1 (en) 2022-08-26 2024-02-29 Suven Life Sciences Limited HETERO-ROMATIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2025146624A1 (en) 2024-01-03 2025-07-10 Pi Industries Ltd. Bicyclic heterocyclic amides for combating phytopathogenic fungi

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS536156B2 (es) 1972-10-30 1978-03-04
ES2271967T3 (es) 1996-03-29 2007-04-16 Duphar International Research B.V Compuestos de piperazina y piperidina.
EP1382607B1 (en) * 1998-12-31 2009-08-19 Ipsen Pharma Prenyl transferase inhibitors
EP1189900B1 (en) * 1999-06-30 2004-01-14 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
AU8066701A (en) 2000-07-20 2002-02-05 Neurogen Corp Capsaicin receptor ligands
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
JP2005515961A (ja) 2001-05-22 2005-06-02 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド：置換１−ベンジル−４−アリールピペラジン類似体
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
KR20040090979A (ko) 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. 히스톤 데아세틸레이즈의 신규한 억제제
WO2004009587A1 (en) 2002-07-22 2004-01-29 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
WO2005074645A2 (en) 2004-02-03 2005-08-18 Chemocentryx, Inc. Methods and compositions for modulating angiogenesis
AU2006230674A1 (en) 2004-03-18 2006-11-16 The Brigham And Women's Hospital, Inc. Methods for the Treatment of Synucleinopathies
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
US7417062B2 (en) * 2004-09-29 2008-08-26 Chemocentryx, Inc. Substituted arylamides
JP2008534481A (ja) 2005-03-23 2008-08-28 アストラゼネカ アクチボラグ インスリン様増殖因子−１受容体活性の阻害剤としての２−アゼチジニル−４−（１ｈ−ピラゾール−３−イルアミノ）ピリミジン
JP2009501156A (ja) * 2005-06-29 2009-01-15 ケモセントリックス，インコーポレイティド 置換ｎ−シンナミルベンズアミド
WO2007059108A2 (en) * 2005-11-10 2007-05-24 Chemocentryx, Inc. Substituted quinolones and methods of use
WO2007111275A1 (ja) 2006-03-24 2007-10-04 The University Of Tokyo シグナル伝達阻害方法、それに用いるシグナル伝達阻害剤およびその用途
WO2007126935A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Diazepan orexin receptor antagonists
US7671069B2 (en) * 2006-03-30 2010-03-02 Chemocentryx, Inc. Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7
US7807704B2 (en) * 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
DK2049529T3 (da) 2006-07-14 2010-11-29 Merck Sharp & Dohme Substituerede diazepan-orexin-receptor- antagonister
KR20090029274A (ko) 2006-07-21 2009-03-20 아이알엠 엘엘씨 Ｉｔｐｋｂ 억제제로서의 화합물 및 조성물
WO2008020229A2 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
WO2008079849A2 (en) 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
WO2008112156A1 (en) 2007-03-08 2008-09-18 Altiris Therapeutics Chemokine receptor modulators
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US20110014121A1 (en) 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
US8853202B2 (en) 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
CN102271681B (zh) * 2008-11-04 2014-11-12 凯莫森特里克斯股份有限公司 Cxcr7调节剂
GB0822981D0 (en) * 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CN102372717B (zh) * 2010-08-20 2014-06-18 和记黄埔医药（上海）有限公司 吡咯并嘧啶类化合物及其用途
MX2013001970A (es) * 2010-08-20 2013-08-09 Hutchison Medipharma Ltd Compuestos de pirrolopirimidina y usos de los mismos.
TWI642670B (zh) 2010-09-14 2018-12-01 伊塞利克斯公司 Ｐｉ３ｋ-德爾塔抑制劑以及其應用和生產方法
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
KR102196374B1 (ko) 2012-11-29 2020-12-31 케모센트릭스, 인크. Cxcr7 길항제
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
JP7590084B2 (ja) 2018-12-12 2024-11-26 ケモセントリックス，インコーポレイティド 癌治療のためのｃｘｃｒ７阻害剤

Also Published As

Publication number Publication date
CA2892042A1 (en) 2014-06-05
US20160145259A1 (en) 2016-05-26
US20220127272A1 (en) 2022-04-28
DK2925745T3 (en) 2018-07-23
IL238974A0 (en) 2015-07-30
RU2649004C2 (ru) 2018-03-29
EP2925745B1 (en) 2018-04-04
PT2925745T (pt) 2018-08-08
RU2015125544A (ru) 2017-01-10
US20140154179A1 (en) 2014-06-05
HK1214264A1 (en) 2016-07-22
US9783544B2 (en) 2017-10-10
US10287292B2 (en) 2019-05-14
JP6272897B2 (ja) 2018-01-31
WO2014085490A1 (en) 2014-06-05
AU2013352304A1 (en) 2015-06-04
ES2681593T3 (es) 2018-09-14
SG11201504212WA (en) 2015-06-29
JP2016502538A (ja) 2016-01-28
MX2015006412A (es) 2015-10-29
BR112015012366A8 (pt) 2019-10-01
US11059825B2 (en) 2021-07-13
CA2892042C (en) 2022-06-14
KR102196374B1 (ko) 2020-12-31
AU2013352304B2 (en) 2017-08-31
KR20160002667A (ko) 2016-01-08
CN105189484A (zh) 2015-12-23
BR112015012366A2 (pt) 2017-07-11
IL238974B (en) 2019-03-31
AU2013352304C1 (en) 2018-03-22
EP2925745A1 (en) 2015-10-07
US20180086766A1 (en) 2018-03-29
US11834452B2 (en) 2023-12-05
US9169261B2 (en) 2015-10-27
CN105189484B (zh) 2018-05-04
EP2925745A4 (en) 2016-06-15
US20200095251A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
MX2015006412A (es) Antagonistas de cxcr7.
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
DOP2014000058A (es) 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante
MX2019009695A (es) Inhibidores espirociclicos de catepsina c.
TN2016000017A1 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
CR20150629A (es) Compuestos químicos
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CL2014002640A1 (es) Compuestos pirrolidin, piperidin o azepan sustituidos, inhibidores de met-ap2; procedimiento para prepararlos; y medicamento que los contiene.
UY33539A (es) Compuestos químicos alk
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
NI201500050A (es) Benzamidas
NI201500096A (es) Compuesto químicos
BR112013018290A2 (pt) antagonistas de receptor 2 ativado por protease (par2)
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
BR112014025041B8 (pt) Composição farmacêutica
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
MX2016006509A (es) Compuestos triciclicos de piperidina.
CO6831981A2 (es) Productos médicos para uso en enfermedades relacionadas con infecciones microbianas en el tracto aerodigestivo superior

Legal Events

Date Code Title Description
FG Grant or registration